9 results on '"Lev-Tov H"'
Search Results
2. Wound care for patients with hidradenitis suppurativa: Recommendations of an international panel of experts.
- Author
-
Chopra D, Anand N, Brito S, Coutts PM, George R, Kimball AB, Kirsner RS, Alavi A, and Lev-Tov H
- Subjects
- Humans, Patients, Hidradenitis Suppurativa therapy
- Abstract
Competing Interests: Conflicts of interest Dr Alavi serves in the board of HSF, as investigator for BI and Processa and consultant 23 for AbbVie, BI, InflaRx, Novartis, UCB. Dr Lev-Tov is the founder, own stock and have a podcast for 24 Learnskin.com; consults for Abbvie Inc, Next Science Inc, Novartis Inc, Pfizer Inc; is a clinical trialist 25 for Incyte Inc, Medline Inc, Molnlyke Inc, Moonlake Inc, Novartis Inc, Sigvaris Inc, Solascure Inc, 26 Tissue Tech Inc, UCB Inc; and recieves research grant support for Essity Inc, Next Science Inc, 27 Sigvaris Inc, Vomaris Inc. Drs Chopra, Anand, Authors Brito, Coutts, Drs George, Kimball, and Kirsner have no conflicts of interest to declare.
- Published
- 2023
- Full Text
- View/download PDF
3. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.
- Author
-
Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, Alikhan A, Daveluy SD, Delorme I, Goldfarb N, Gulliver W, Hamzavi I, Jaleel T, Kimball AB, Kirby JS, Kirchhof MG, Lester J, Lev-Tov H, Lowes MA, Micheletti R, Orenstein LA, Piguet V, Sayed C, Tan J, and Naik HB
- Subjects
- Canada epidemiology, Comorbidity, Female, Humans, Hidradenitis Suppurativa diagnosis, Hidradenitis Suppurativa epidemiology, Hidradenitis Suppurativa etiology, Metabolic Syndrome epidemiology, Pyoderma Gangrenosum epidemiology
- Abstract
Background: Hidradenitis suppurativa (HS) is associated with comorbidities that contribute to poor health, impaired life quality, and mortality risk., Objective: To provide evidence-based screening recommendations for comorbidities linked to HS., Methods: Systematic reviews were performed to summarize evidence on the prevalence and incidence of 30 comorbidities in patients with HS relative to the general population. The screening recommendation for each comorbidity was informed by the consistency and quality of existing studies, disease prevalence, and magnitude of association, as well as benefits, harms, and feasibility of screening. The level of evidence and strength of corresponding screening recommendation were graded by using the Strength of Recommendation Taxonomy (SORT) criteria., Results: Screening is recommended for the following comorbidities: acne, dissecting cellulitis of the scalp, pilonidal disease, pyoderma gangrenosum, depression, generalized anxiety disorder, suicide, smoking, substance use disorder, polycystic ovary syndrome, obesity, dyslipidemia, diabetes mellitus, metabolic syndrome, hypertension, cardiovascular disease, inflammatory bowel disease, spondyloarthritis, and sexual dysfunction. It is also recommended to screen patients with Down syndrome for HS. The decision to screen for specific comorbidities may vary with patient risk factors. The role of the dermatologist in screening varies according to comorbidity., Limitations: Screening recommendations represent one component of a comprehensive care strategy., Conclusions: Dermatologists should support screening efforts to identify comorbid conditions in HS., Competing Interests: Conflicts of interest Dr Garg has served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, Incyte, Janssen, Novartis, Pfizer, UCB, and Viela Bio; has received honoraria from AbbVie, Amgen, Boehringer Ingelheim, Incyte, Janssen, Novartis, Pfizer, UCB, and Viela Bio; and has received grants: from AbbVie and the National Psoriasis Foundation. Dr Alavi has served as a consultant for AbbVie, Boehringer Ingelheim, Incyte, Janssen, Pfizer, UCB, Actelion, Celgene, Galderma, GlaxoSmithKline, Leo Pharma, Novartis, Sanofi-Genzyme, Kymera, Eli Lily, InflaRx, Sanofi, and Bausch; has received honoraria from AbbVie, Boehringer Ingelheim, Incyte, Janssen, Pfizer, UCB, Actelion, Celgene, Galderma, GlaxoSmithKline, Leo Pharma, Novartis, Genzyme, Kymera, Eli Lily, Sanofi, and Bausch; has received grants from AbbVie; and has received donations of medical equipment from Galderma and Swift. Dr Alhusayen has served as a consultant for AbbVie, Janssen, Leo Pharma, Hidramed Solutions and has received honoraria from AbbVie, and Eli Lilly. Dr Daveluy has served as a consultant for AbbVie; has received honoraria from AbbVie; has served on the speakers bureau for AbbVie; and has received grants from AbbVie, InflaRx, Regeneron, and Pfizer. Dr Delorme has served as a consultant for AbbVie, Celgene, Eli-Lilly, Janssen, Novartis, and Sanofi-Genzyme; has received honoraria from AbbVie, Amgen, Avene, Celgene, Eli Lilly, Janssen, Novartis, and UCB Pharma; has served on the speakers bureau for AbbVie, Bausch Health, Celgene, Eli Lilly, Janssen, Novartis, and Sanofi Genzyme; and has received grants from AbbVie, InflaRx, Regeneron, and Pfizer. Dr Gulliver has served as a consultant for AbbVie, Amgen, Bausch Health, Celgene, Cipher, Eli Lilly, Janssen, LEO Pharma, Novartis, PeerVoice, Pfizer, Sanofi-Genzyme, UCB, and Valeant; has received honoraria from AbbVie, Amgen, Bausch Health, Celgene, Cipher, Eli Lilly, Janssen, LEO Pharma, Novartis, PeerVoice, Pfizer, Sanofi-Genzyme, UCB, and Valeant; and has received grants from AbbVie, Amgen, Eli Lilly, Novartis, and Pfizer. Dr Hamzavi has served as a consultant for Incyte, UCB, and Pfizer and has received grants from Lenicura and Boehringer Ingelheim. Dr Jaleel has served as a consultant for Eli Lilly and ChemoCentryx/IQVIA and has received grants from the Dermatology Foundation and Skin of Color Society. Dr Kimball has served as a consultant for AbbVie, Janssen, Lilly, Novartis, Pfizer, UCB, and Kymera; has received honoraria from AbbVie, Janssen, Lilly, Novartis, Pfizer, UCB, and Kymera; and has received royalties from Pfizer, Trifecta, and UCB. Dr Kirby has served as a consultant for AbbVie, ChemoCentryx, Incyte, Novartis, and UCB; has received honoraria from AbbVie, Incyte, and Viela Bio; and has served on the speakers bureau for AbbVie. Dr Kirchhof has served as a consultant for AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, UCB, Sanofi-Genzyme; has served on the speakers bureau for AbbVie, Janssen, Novartis, Pfizer, UCB, and Sanofi-Genzyme; and has received grants from the Canadian Dermatology Foundation. Dr Lev-Tov has served as a consultant for Pfizer, Mölnlycke, and NextScience; has received honoraria from Essity; has received grants from NextScience and Essity; and has received donations of medical equipment from Essity, Mölnlycke, and NextScience. Dr Lowes has served as a consultant for AbbVie, Janssen, Viela Bio, Almirall, BSN, Incyte, Janssen, Kymera, and XBiotech. Dr Naik has served as a consultant for Boehringer Ingelheim, Janssen, and 23andme and has received grants from AbbVie, Hidradenitis Suppurativa Foundation. Dr Orenstein has received a Hidradenitis Suppurativa Foundation Danby Research Grant. Dr Piguet has served as a consultant for Pfizer, AbbVie, Janssen, UCB, Novartis, Almirall, and Celgene; has received honoraria from Kyowa Kirin Co Ltd, AbbVie, and Novartis; has received grants from AbbVie, Bausch Health, Celgene, Janssen, LEO Pharma, Lilly, NAOS, Novartis, Pfizer, Pierre-Fabre, and Sanofi; and has received a donation of medical equipment from La Roche-Posay. Dr Sayed has served as a consultant for UCB, InflaRx, and AbbVie; has received honoraria from UCB and AbbVie; and has served on the speakers bureau for AbbVie and Novartis. Dr Tan has served as a consultant for Almirall, Bausch, Boots/Walgreens, Botanix, Cipher, Galderma, Incyte, L’Oréal, Novartis, Pfizer, Promius, Sun, and UCB; has received honoraria from Almirall, Bausch, Boots/Walgreens, Botanix, Galderma, L’Oréal, Novartis, Pfizer, Promius, and Sun; has served on the speakers bureau for Galderma and L’Oréal; and has received grants from Incyte and UCB. Drs Alikhan and Goldfarb, Author Lester, Drs Malviya and Micheletti, and Authors Strunk and Wright have no conflicts of interest to declare., (Copyright © 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
4. Wound dressings improve quality of life for hidradenitis suppurativa patients.
- Author
-
Schneider C, Sanchez DP, MacQuhae F, Stratman S, and Lev-Tov H
- Subjects
- Bandages, Humans, Hidradenitis Suppurativa therapy, Quality of Life
- Abstract
Competing Interests: Conflict of interest Dr Lev-Tov received a research grant and speaker fees from BSN Medical Inc. Dr Sanchez and Authors Schneider, MacQuhae, and Stratman have no conflicts to disclose.
- Published
- 2022
- Full Text
- View/download PDF
5. Examining risk factors and preventive treatments for first venous leg ulceration: A cohort study.
- Author
-
Darwin E, Liu G, Kirsner RS, and Lev-Tov H
- Subjects
- Adolescent, Adult, Age Factors, Anticoagulants therapeutic use, Antihypertensive Agents therapeutic use, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Male, Middle Aged, Pain Management, Recurrence, Retrospective Studies, Risk Factors, Sex Factors, Stockings, Compression, Varicose Ulcer etiology, Young Adult, Varicose Ulcer prevention & control, Venous Insufficiency complications, Venous Insufficiency therapy
- Abstract
Background: Large studies that examine risk factors for first occurrence of venous leg ulcerations are needed to guide management., Objective: To investigate factors associated with development of first occurrence of venous leg ulcerations., Methods: A retrospective cohort study using a validated national commercial claims database of patients with venous insufficiency. Subjects were followed to determine whether they developed first occurrence of venous leg ulcerations, and risk and protective factors were analyzed., Results: Adjusted hazard ratio (AHR) for comorbidities demonstrated an increased risk in men (AHR 1.838; 95% confidence interval [CI] 1.798-1.880), older age (45-54 years: AHR 1.316, 95% CI 1.276-1.358; 55-64 years, AHR 1.596, 95% CI 1.546-1.648), history of nonvenous leg ulceration (AHR 3.923; 95% CI 3.699-4.161), anticoagulant use (AHR 1.199; 95% CI 1.152-1.249), antihypertensive use (AHR 1.067; 95% CI 1.040-1.093), and preexisting venous insufficiency including chronic venous insufficiency (AHR 1.244; 95% CI 1.193-1.298), edema (AHR 1.224; 95% CI 1.193-1.256), and chronic venous hypertension (AHR 1.671; 95% CI 1.440-1.939). Possible protective factors were having venous surgery (AHR 0.454; 95% CI 0.442-0.467), using compression stockings (AHR 0.728; 95% CI 0.705-0.753), using prescribed statin medications (AHR 0.721; 95% CI 0.700-0.743), and using pain medications (AHR 0.779; 95% CI 0.757-0.777)., Limitations: Risk of misclassification, given the use of International Classification of Diseases, Ninth Revision codes. Possible confounding factors such as body mass index could not be adequately controlled with these codes., Conclusion: The new evidence presented supports a paradigm shift toward venous leg ulceration prevention., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
6. Clinical considerations for managing dermatology patients on systemic immunosuppressive or biologic therapy, or both, during the COVID-19 pandemic.
- Author
-
Sanchez DP, Kirsner RS, and Lev-Tov H
- Subjects
- Biological Products adverse effects, Biological Products standards, COVID-19, Coronavirus Infections epidemiology, Coronavirus Infections immunology, Dermatologic Agents standards, Dermatology methods, Dermatology standards, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents standards, Incidence, Meta-Analysis as Topic, Placebos adverse effects, Pneumonia, Viral epidemiology, Pneumonia, Viral immunology, Practice Guidelines as Topic, Randomized Controlled Trials as Topic, Respiratory Tract Infections chemically induced, Respiratory Tract Infections immunology, SARS-CoV-2, Skin Diseases immunology, Systematic Reviews as Topic, Betacoronavirus immunology, Coronavirus Infections prevention & control, Dermatologic Agents adverse effects, Pandemics prevention & control, Pneumonia, Viral prevention & control, Respiratory Tract Infections epidemiology, Skin Diseases drug therapy
- Published
- 2020
- Full Text
- View/download PDF
7. Trends in utilization of topical medications for treatment of rosacea in the United States (2005-2014): A cohort analysis.
- Author
-
Lev-Tov H, Rill JS, Liu G, and Kirby JS
- Subjects
- Administration, Cutaneous, Adult, Anti-Bacterial Agents administration & dosage, Cohort Studies, Dermatologic Agents administration & dosage, Dicarboxylic Acids administration & dosage, Drug Costs statistics & numerical data, Drug Therapy, Combination, Drugs, Generic economics, Female, Humans, Male, Metronidazole administration & dosage, Middle Aged, Retrospective Studies, United States, Anti-Bacterial Agents therapeutic use, Dermatologic Agents therapeutic use, Dicarboxylic Acids therapeutic use, Drug Utilization trends, Metronidazole therapeutic use, Rosacea drug therapy, Rosacea economics
- Published
- 2019
- Full Text
- View/download PDF
8. Epidemiology and treatment of angiolymphoid hyperplasia with eosinophilia (ALHE): A systematic review.
- Author
-
Adler BL, Krausz AE, Minuti A, Silverberg JI, and Lev-Tov H
- Subjects
- Humans, Angiolymphoid Hyperplasia with Eosinophilia epidemiology, Angiolymphoid Hyperplasia with Eosinophilia therapy
- Abstract
Background: Current knowledge of angiolymphoid hyperplasia with eosinophilia (ALHE) derives from retrospective reports and case series, leading to a nonevidence-based treatment approach., Objective: We sought to systematically review the literature relating to cutaneous ALHE to estimate its epidemiology and treatment outcomes., Methods: A literature search of PubMed, EMBASE, Web of Science, and Google Scholar was conducted. Articles detailing cases of histologically confirmed cutaneous ALHE were included., Results: In all, 416 studies were included in the review, representing 908 patients. There was no sex predominance among patients with ALHE. Mean age at presentation was 37.6 years. There was a significant association between presence of multiple lesions and pruritus, along with bleeding. Surgical excision was the most commonly reported treatment for ALHE. Treatment failure was lowest for excision and pulsed dye laser. Mean disease-free survival after excision was 4.2 years. There were higher rates of recurrence postexcision with earlier age of onset, longer duration of disease, multiple lesions, bilateral lesions, pruritus, pain, and bleeding., Limitations: Potential for publication bias is a limitation., Conclusions: Surgical excision appears to be the most effective treatment for ALHE, albeit suboptimal. Pulsed dye and other lasers may be effective treatment options. More studies are needed to improve the treatment of ALHE., (Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
9. Successful treatment of a chronic venous leg ulcer using a topical beta-blocker.
- Author
-
Lev-Tov H, Dahle S, Moss J, and Isseroff RR
- Subjects
- Administration, Oral, Administration, Topical, Adrenergic beta-Antagonists therapeutic use, Aged, Biopsy, Needle, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Follow-Up Studies, Humans, Immunohistochemistry, Male, Severity of Illness Index, Treatment Outcome, Ultrasonography, Doppler methods, Varicose Ulcer diagnostic imaging, Wound Healing physiology, Pentoxifylline therapeutic use, Timolol therapeutic use, Varicose Ulcer drug therapy, Varicose Ulcer pathology, Wound Healing drug effects
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.